Denver Business Journal
The headlines for AspenBio Pharma Inc. the last two years would be enough to shake just about anyone’s confidence in a company, but not that of the Castle Rock medical device maker.
Its key product — a device to help doctors diagnose appendicitis — showed disappointing accuracy in 2010 tests. AspenBio’s share price plummeted. Executives were replaced.
Twice in the past year, AspenBio organized reverse stock splits to keep the company’s stock listed on the Nasdaq exchange.
But, with all that now in its past, AspenBio (Nasdaq: APPY) may be poised to become a bright spot in Colorado’s bioscience industry. ...